Amgen Inc.

Amgen Inc.
Share
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. A sponsor of the 2012 INS conference, Amgen invites you a dinner presentation about anemia awareness. Visit our booth for details.

Amgen Inc.

 •  August 31

THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) based on the overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial demonstrating that KYPROLIS® (carfilzomib) and...

Amgen Inc.

 •  August 30

THOUSAND OAKS, Calif., Aug. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a new analysis showed lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha® (evolocumab) reduced the risk of cardiovascular events in a sub-group of patients with a history of stroke from the Repatha cardiovascular outcomes study...

Amgen Inc.

 •  August 30

THOUSAND OAKS, Calif., Aug. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from an exploratory virtual histology sub-study of the Repatha® (evolocumab) GLAGOV Phase 3 coronary intravascular ultrasound imaging trial that looked at coronary artery plaque composition. While virtual histology demonstrated an increase in dense...

Amgen Inc.

 •  August 28

THOUSAND OAKS, Calif., Aug. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that showed a statistically significant relationship between lower achieved low-density lipoprotein cholesterol (LDL-C) levels and lower cardiovascular event rates in...

Amgen Inc.

 •  August 24

THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that KYPROLIS® (carfilzomib) administered at 56 mg/m2 twice weekly and dexamethasone (Kd56) reduced...

Amgen Inc.

 •  August 24

THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a new Repatha® (evolocumab) economic analysis published in the Journal of the American Medical Association (JAMA) Cardiology. The study identifies the clinical and economic consequences of treating a population of patients at high-risk of...

Amgen Inc.

 •  July 28

THOUSAND OAKS, Calif., July 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Amgen's supplemental Biologics License Application (sBLA) for Repatha® (evolocumab), a PCSK9 inhibitor. If approved by the FDA, the U.S. Prescribing Information for Repatha will...

Amgen Inc.

 •  July 14

THOUSAND OAKS, Calif., July 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing application to the European Medicines Agency (EMA) to include overall survival (OS) data from the Phase 3 head-to-head...

Amgen Inc.

 •  July 13

THOUSAND OAKS, Calif., July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of overall survival (OS), demonstrating that KYPROLIS® (carfilzomib), lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent...

Amgen Inc.

 •  July 13

THOUSAND OAKS, Calif., July 13, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Companies will discuss data supporting the ABP 215 Biologics License Application (BLA) with the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA). ABP 215 is a biosimilar candidate to...